Stevensville

Researchers are exploring new minimally invasive, non-drug treatments for osteoarthritis (OA), a common condition causing joint pain and disability. This study focuses on using a person's own stem/stromal cells combined with high-dose platelet-rich plasma (HD-PRP) to help relieve OA symptoms and support tissue repair. The trial aims to track progress over time and evaluate the long-term effects of these cellular therapies on joint health and pain, especially since traditional surgeries and medical treatments have not shown consistent long-term success. The study includes three different treatment approaches: first, guided biocellular therapy using tissue stromal vascular fraction (tSVF) plus platelet-rich plasma; second, a combination of tSVF, platelet-rich plasma, and cellular stromal vascular fraction (cSVF) concentrates; and third, systemic delivery of cSVF suspended in sterile normal saline via intravenous infusion. Treatments involve harvesting cells from the patient's own tissues, preparing concentrates of healing factors, and using ultrasound guidance for precise placement. Follow-up continues for at least two years after treatment, with separate tracking for patients receiving multiple treatments or treatments at multiple sites. Participants will undergo clinical exams, imaging tests including ultrasound, and pain assessments at various times throughout the study to monitor changes in joint structure and function. Researchers will measure pain using visual analog scales and numeric pain rating scales, track any complications, and evaluate ultrasound changes from baseline at intervals up to one year and beyond. Participants are also asked to report any adverse events during the study. The goal is to better understand the safety and outcomes of these regenerative therapies in managing OA and related joint degeneration.